Toggle light / dark theme

A mechanism that causes autism, schizophrenia, Alzheimer’s and other conditions and is shared by mutations in the genes ADNP and SHANK3 has been unraveled by Tel Aviv University researchers who developed an experimental drug they found to be effective in animal models.

The drug could also be suitable for treating a range of rare syndromes that impair brain functions, said the scientists. The researchers were led by Prof. Illana Gozes from the Department of Human Molecular Genetics and Biochemistry at TAU’s Sackler Faculty of Medicine and the Sagol School of Neuroscience. The experimental drug, called Davunetide, had previously been developed in her lab.

The paper, which the team called a “scientific breakthrough,” was published in the scientific journal Molecular Psychiatry under the title “SH3-and actin-binding domains connect ADNP and SHANK3, revealing a fundamental shared mechanism underlying autism.”

“Spacecraft antenna designs are challenging due to their conflicting requirements for high gain, wide bandwidth, and low weight,” Mitsubishi announced. “High gain and wide bandwidth necessarily require a large aperture, but economical orbital deployment conventionally dictates that designs be lightweight and small enough to fit or fold inside a launch vehicle or satellite deployment mechanism.”

Mitsubishi also claimed that, with its new technology, ‘additive-manufacturing in space has now become possible.’ However, it’s worth noting that the International Space Station already features a 3D printer launched to the orbital station back in 2014. The European Space Agency also announced last year it would experiment with 3D printing in space using scrap metals from the Moon.

Still, the company’s new method has the potential to reduce the cost of satellite launches significantly, and it could pave the way for the construction of other vital parts for future space missions.